229 related articles for article (PubMed ID: 20332475)
1. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
2. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
3. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
5. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
7. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
8. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
9. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
10. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
11. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
[TBL] [Abstract][Full Text] [Related]
12. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
13. Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma.
Yamada K; Higashi K; Nagahori H; Saito K
Cancer Biomark; 2020; 27(1):121-128. PubMed ID: 31771041
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
15. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
17. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
18. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
19. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
20. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
